Media In the News Press Releases CareersContact Us Advancing Topical Therapeutics IN Rare Disease Oncology & AESTHETIC DermatologySign up for the latest news and insights from our team Sign Up © 2024 DermBiont, Inc. All rights reserved....
DermBiont today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and ...